3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
10
Phase 1
5
Phase EARLY_PHASE1
1
Phase 3
1
Phase 2/3
1
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
2
Other hematologic neoplasm
2
Plasma cell
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Conditions
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Multiple Myeloma
1
Melanoma
1
Laryngeal Neoplasms
1
Hematologic Neoplasms
1
Glioma
1
Erdheim-Chester Disease
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Oxaliplatin
49
Fluorouracil
46
Capecitabine
41
Cisplatin
36
Gemcitabine
29
Leucovorin
27
Bevacizumab
21
Drug Therapy
20
Paclitaxel
15
Folfox protocol
15
Radiotherapy
14
Irinotecan
14
apatinib
11
Neoadjuvant Therapy
11
Docetaxel
11
sintilimab
9
S 1 (combination)
9
Trastuzumab
8
Sorafenib
8
Nivolumab
8
Surgical Procedures, Operative
7
Magnetic Resonance Spectroscopy
7
lenvatinib
6
atezolizumab
6
XELOX
6
Cetuximab
6
Albumin-Bound Paclitaxel
6
130-nm albumin-bound paclitaxel
6
tislelizumab
5
pembrolizumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Vemurafenib
×
Gastrointestinal
×
Clear all
NCT05768178
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled